SCHEMBL8073142

SCHEMBL8073142

Cc1cc2ccc(CO)cc2[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.54
▸ DAO P14920 4/20 0.54
▸ DDO Q99489 2/20 0.46
▸ PARP1 P09874 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ MAOA P21397 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ GRIA1 P42261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8075624 0.83 BRD4 (0.54) BRD4DAODDOKDM4EALDH1A1
SCHEMBL31159560 0.83 BRD4 (0.54) BRD4DAODDOKDM4EALDH1A1
SCHEMBL25093890 0.82 DAO (0.60) DAOPARP1KDM4EALDH1A1HSD17B10
SCHEMBL30493556 0.82 DAO (0.60) DAOPARP1KDM4EALDH1A1HSD17B10
SCHEMBL30908505 0.80 DAO (0.50) DAODDOPARP1KDM4EALDH1A1
SCHEMBL24215891 0.79 MAPT (0.44) DAOKDM4EALDH1A1HSD17B10MAOA
SCHEMBL30460450 0.79 MAPT (0.44) DAOKDM4EALDH1A1HSD17B10MAOA
SCHEMBL1038241 0.77 BRD4 (0.59) BRD4DAODDOKDM4EALDH1A1
SCHEMBL15478601 0.77 DAO (0.68) BRD4DAODDOKDM4EALDH1A1
SCHEMBL3064748 0.75 CA12 (0.48) DAOPARP1CA12CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 — — US disclosed
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 — — US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 — — US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 — — US disclosed
WO-2009053373-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS PARP1, PARP2, PARP11 BRD4 211/4885DAO 3543/4885DDO 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback